Wockhardt Ltd (WOCKPHARMA)
₹2,224.00
Mkt cap
₹35,878 Cr
P/E ratio
90.00
P/B
7.32
Div yield
0.00%
ROE
6.11%
ROCE
7.55%
EPS (TTM)
₹24.71
Book value
₹304
52W range
1,100–2,224
Sector
Healthcare
Price history
Previous close
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
NSE WOCKPHARMABSE 532300
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
0.00% from high₹2,224
₹1,100+102.13% from low₹2,224
Current
₹2,224.00
Prev close
₹2,212.80
Day
+0.51%
Price performance
1D
+0.51%
1W
+20.18%
1M
+15.16%
3M
+21.33%
6M
+70.40%
1Y
+57.16%
YTD
+58.16%
Financials
Revenue, profit & margin
P/E ratio
90.0×
WOCKPHARMA is 157% above the sector median of 35.1×
WOCKPHARMA90.0×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 | |
| Expenses | 628 | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 | 737 | |
| Operating Profit | 16 | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 | 192 | |
| OPM % | 2.5% | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% | 23% | 20% | 23% | 21% | |
| Other Income | 0 | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 | 21 | 15 | 67 | 31 | |
| Interest | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 | 52 | |
| Depreciation | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 | 55 | |
| Profit before tax | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 | 67 | 189 | 116 | |
| Tax % | 15% | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% | 10% | 9% | 13% | 8% | |
| Net Profit | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 | 82 | 61 | 164 | 107 | |
| EPS in Rs | -9.30 | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 | 4.80 | 3.63 | 10.22 | 6.52 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.45% · closed higher next day 24 of last 59
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Nov '23◦ | 14 Feb '24◦ | 28 May '24◦ | 9 Aug '24◦ | 13 Nov '24◦ | 7 Feb '25 | 29 May '25◦ | 8 Aug '25 | 3 Nov '25 | 10 Feb '26 | 4 May '26◦ | 10 Aug '26◦ |
| Earnings day | −1.47% | −0.96% | +0.56% | +3.03% | −1.62% | −3.13% | +8.80% | −3.25% | +10.32% | +1.27% | +7.86% | −1.13% |
| +1 day | +12.51% | +8.62% | −4.46% | −2.10% | −4.48% | −7.98% | +8.85% | −3.86% | +6.54% | −0.64% | +20.48% | −4.34% |
| +5 days | +16.54% | +26.44% | −7.06% | +2.81% | +8.88% | −16.11% | +11.78% | −0.94% | +3.93% | −1.06% | +10.20% | −3.69% |
| +15 days | +19.96% | +23.53% | +2.34% | +10.24% | +17.35% | −27.32% | +28.51% | −7.01% | −0.88% | −8.57% | +19.31% | −4.17% |
| +30 days | +48.89% | +33.41% | +58.37% | +4.76% | +19.12% | −13.60% | +30.46% | −2.94% | +5.91% | −15.16% | +41.95% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202649.09%Promoter
Promoters49.09%
FIIs7.23%0.14
DIIs9.24%1.72
Public34.44%1.60
Government0.02%0.02
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| WOCKPHARMA | ₹2,208.00 | 89.99 | 35,878 | 0.00% | 107 | +973.63% | 929 | +25.88% | 7.55% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts11
Credit ratings6
Announcements5
Disclosure under Regulation 30A of LODR 25 Aug - Received 21 Aug 2026 customs order imposing ₹5 crore penalty and ₹10 crore redemption fine on Wockhardt for API misclassification.Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Aug - Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper …Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 10 AugShareholder Meeting / Postal Ballot-Outcome of AGM 10 AugAnnouncement under Regulation 30 (LODR)-Monitoring Agency Report 10 Aug - Crisil report for June 30, 2026 shows no deviation in Wockhardt’s QIP proceeds use.